Last reviewed · How we verify
NCT04722029: ADV-VSTS
Pilot Study of Haploidentical Donor Adenovirus Specific T-lymphocytes to Treat Refractory Adenovirus Infections
Phase 1, PHASE2 trial testing Adenovirus Specific T lymphocytes in Adenovirus Infection in 12 participants. Currently enrolling.
1 October 2026
Quick facts
| Lead sponsor | Nationwide Children's Hospital |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 1 October 2021 |
| Primary completion | 1 October 2026 |
| Estimated completion | 1 October 2027 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Adenovirus Specific T lymphocytes — full drug profile →
Conditions studied
- Adenovirus Infection — all drugs for Adenovirus Infection →
Sponsor
Nationwide Children's Hospital
Who can join
Under 60, any sex, with Adenovirus Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This open-label, single-arm, phase I/II clinical trial will assess the safety and efficacy of related donor adenovirus-specific T lymphocytes isolated from whole blood or leukapheresis products. The adenovirus-specific T lymphocytes will be generated automatically by the CliniMACS Prodigy using the CliniMACS Cytokine Capture System (IFN-γ) after incubation with MACS GMP PepTivator Peptide Pools of Hexon 5 for enrichment.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04722029
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Adenovirus Infection
Currently open trials in the same condition.
- NCT05101213 — Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus S · Phase 1 · recruiting
- NCT03475212 — Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation · Phase 1, PHASE2 · active not recruiting
Other Nationwide Children's Hospital trials
Trials by the same sponsor.
- NCT07035912 — Novel PIONEER© Protocol: RCT · NA · not yet recruiting
- NCT07435792 — TetraGraph to Evaluate Onset and Recovery Times of Rocuronium · NA · not yet recruiting
- NCT07026942 — Phase I/II Clinical Trial of Universal Donor CD33 CAR Natural Killer Cells for AML · Phase 1, PHASE2 · not yet recruiting
- NCT06795126 — Little NIRVANA for Pediatric Pain and Anxiety · NA · enrolling by invitation
- NCT06854991 — Healthy Children and Virtual Reality Mediation of Simulated Pain · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04722029 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nationwide Children's Hospital
- Last refreshed: 13 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04722029.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing